As we predicted in yesterday's post, FDA approved a new biosimilar product, Sandoz's Erelzi (etanercept-szzs), which is a biosimilar to Amgen's Enbrel (etanercept), on August 30th. FDA's decision comes shortly after its Arthritis Advisory Committee voted unanimously in support of approving the biosimilar. FDA followed its draft naming guidance and assigned the biosimilar's non-proprietary name using the reference product's drug substance name followed by a nonsense four-letter suffix. Erelzi becomes the third biosimilar to receive FDA approval (the second for Novartis subsidiary Sandoz) and is indicated for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis, similar to Enbrel. However, Erelzi cannot be launched commercially until at least 6 months after Sandoz provides Amgen with the mandatory notice required under the law, which the Federal Circuit Court of Appeals has affirmed cannot be provided until after FDA approves the biosimilar application.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.